Kite boasts of faster Yescarta manufacturing times

24 April 2023
kite_large-jpg

Gilead Sciences (Nasdaq: GILD) subsidiary company Kite has announced the publication of a new European analysis of commercial manufacturing experience of Yescarta (axicabtagene ciloleucel).

The analysis shows a median European manufacturing turnaround time of 19 days for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) during a period from 2020 to 2022. This compares to 25 days from the initial two-year analysis from 2018 to 2022.

An improvement in delivery success rate since the initial two-year period was also observed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology